Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses

被引:32
作者
Russell, Charles J. [1 ,2 ]
Hurwitz, Julia L. [1 ,2 ]
机构
[1] St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA
[2] Univ Tennessee, Hlth Sci Ctr, Dept Microbiol Immunol & Biochem, Memphis, TN USA
关键词
Sendai virus; paramyxovirus; pediatric vaccine; respiratory tract; antibody; T cell; vaccine vector; intranasal; RESPIRATORY SYNCYTIAL VIRUS; AFRICAN-GREEN MONKEYS; M-PROTEIN BINDS; HUMAN PARAINFLUENZA; FUSION PROTEIN; COTTON RATS; NEUTRALIZING ANTIBODY; MEMBRANE-FUSION; B-CELL; PROTECTIVE IMMUNITY;
D O I
10.1586/14760584.2016.1114418
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human paramyxoviruses are the etiological agents for life-threatening respiratory virus infections of infants and young children. These viruses, including respiratory syncytial virus (RSV), the human parainfluenza viruses (hPIV1-4) and human metapneumovirus (hMPV), are responsible for millions of serious lower respiratory tract infections each year worldwide. There are currently no standard treatments and no licensed vaccines for any of these pathogens. Here we review research with which Sendai virus, a mouse parainfluenza virus type 1, is being advanced as a Jennerian vaccine for hPIV1 and as a backbone for RSV, hMPV and other hPIV vaccines for children.
引用
收藏
页码:189 / 200
页数:12
相关论文
共 135 条
  • [1] Safety and Immunogenicity of an Intranasal Sendai Virus-Based Human Parainfluenza Virus Type 1 Vaccine in 3-to 6-Year-Old Children
    Adderson, Elisabeth
    Branum, Kristen
    Sealy, Robert E.
    Jones, Bart G.
    Surman, Sherri L.
    Penkert, Rhiannon
    Freiden, Pamela
    Slobod, Karen S.
    Gaur, Aditya H.
    Hayden, Randall T.
    Allison, Kim
    Howlett, Nanna
    Utech, Jill
    Allay, Jim
    Knight, James
    Sleep, Susan
    Meagher, Michael M.
    Russell, Charles J.
    Portner, Allen
    Hurwitz, Julia L.
    [J]. CLINICAL AND VACCINE IMMUNOLOGY, 2015, 22 (03) : 298 - 303
  • [2] Ahmed JA, 2012, BMC INFECT DIS, V12, P1
  • [3] Assembly of Sendai virus: M protein interacts with F and HN proteins and with the cytoplasmic tail and transmembrane domain of F protein
    Ali, A
    Nayak, DP
    [J]. VIROLOGY, 2000, 276 (02) : 289 - 303
  • [4] Immunity and immunological memory following smallpox vaccination
    Amanna, Ian J.
    Slifka, Mark K.
    Crotty, Shane
    [J]. IMMUNOLOGICAL REVIEWS, 2006, 211 : 320 - 337
  • [5] Strategic priorities for respiratory syncytial virus (RSV) vaccine development
    Anderson, L. J.
    Dormitzer, P. R.
    Nokes, D. J.
    Rappuoli, R.
    Roca, A.
    Graham, B. S.
    [J]. VACCINE, 2013, 31 : B209 - B215
  • [6] Respiratory syncytial virus vaccine development
    Anderson, Larry J.
    [J]. SEMINARS IN IMMUNOLOGY, 2013, 25 (02) : 160 - 171
  • [7] Influenza and respiratory syncytial virus (RSV) vaccines for infants: Safety, immunogenicity, and efficacy
    Beeler, Judy A.
    Eichelberger, Maryna C.
    [J]. MICROBIAL PATHOGENESIS, 2013, 55 : 9 - 15
  • [8] Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment
    Bousse, Tatiana
    Chambers, Raychel L.
    Scroggs, Ruth Ann
    Portner, Allen
    Takimoto, Toru
    [J]. VIRUS RESEARCH, 2006, 121 (01) : 23 - 32
  • [9] Respiratory Syncytial Virus Infection in Older Adults: An Under-Recognized Problem
    Branche, Angela R.
    Falsey, Ann R.
    [J]. DRUGS & AGING, 2015, 32 (04) : 261 - 269
  • [10] PROTECTION OF COTTON RATS AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS BY VACCINATION WITH A NOVEL CHIMERIC FG GLYCOPROTEIN
    BRIDEAU, RJ
    WALTERS, RR
    STIER, MA
    WATHEN, MW
    [J]. JOURNAL OF GENERAL VIROLOGY, 1989, 70 : 2637 - 2644